1
|
Saarentaus EC, Havulinna AS, Mars N, Ahola-Olli A, Kiiskinen TTJ, Partanen J, Ruotsalainen S, Kurki M, Urpa LM, Chen L, Perola M, Salomaa V, Veijola J, Männikkö M, Hall IM, Pietiläinen O, Kaprio J, Ripatti S, Daly M, Palotie A. Polygenic burden has broader impact on health, cognition, and socioeconomic outcomes than most rare and high-risk copy number variants. Mol Psychiatry 2021; 26:4884-4895. [PMID: 33526825 PMCID: PMC8589645 DOI: 10.1038/s41380-021-01026-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 12/18/2020] [Accepted: 01/11/2021] [Indexed: 12/29/2022]
Abstract
Copy number variants (CNVs) are associated with syndromic and severe neurological and psychiatric disorders (SNPDs), such as intellectual disability, epilepsy, schizophrenia, and bipolar disorder. Although considered high-impact, CNVs are also observed in the general population. This presents a diagnostic challenge in evaluating their clinical significance. To estimate the phenotypic differences between CNV carriers and non-carriers regarding general health and well-being, we compared the impact of SNPD-associated CNVs on health, cognition, and socioeconomic phenotypes to the impact of three genome-wide polygenic risk score (PRS) in two Finnish cohorts (FINRISK, n = 23,053 and NFBC1966, n = 4895). The focus was on CNV carriers and PRS extremes who do not have an SNPD diagnosis. We identified high-risk CNVs (DECIPHER CNVs, risk gene deletions, or large [>1 Mb] CNVs) in 744 study participants (2.66%), 36 (4.8%) of whom had a diagnosed SNPD. In the remaining 708 unaffected carriers, we observed lower educational attainment (EA; OR = 0.77 [95% CI 0.66-0.89]) and lower household income (OR = 0.77 [0.66-0.89]). Income-associated CNVs also lowered household income (OR = 0.50 [0.38-0.66]), and CNVs with medical consequences lowered subjective health (OR = 0.48 [0.32-0.72]). The impact of PRSs was broader. At the lowest extreme of PRS for EA, we observed lower EA (OR = 0.31 [0.26-0.37]), lower-income (OR = 0.66 [0.57-0.77]), lower subjective health (OR = 0.72 [0.61-0.83]), and increased mortality (Cox's HR = 1.55 [1.21-1.98]). PRS for intelligence had a similar impact, whereas PRS for schizophrenia did not affect these traits. We conclude that the majority of working-age individuals carrying high-risk CNVs without SNPD diagnosis have a modest impact on morbidity and mortality, as well as the limited impact on income and educational attainment, compared to individuals at the extreme end of common genetic variation. Our findings highlight that the contribution of traditional high-risk variants such as CNVs should be analyzed in a broader genetic context, rather than evaluated in isolation.
Collapse
Affiliation(s)
- Elmo Christian Saarentaus
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
| | - Aki Samuli Havulinna
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland ,grid.14758.3f0000 0001 1013 0499Finnish Institute for Health and Welfare, Helsinki, Finland
| | - Nina Mars
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
| | - Ari Ahola-Olli
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland ,grid.66859.34Stanley Center for Psychiatric Research, The Broad Institute of Harvard and MIT, Cambridge, MA USA ,grid.32224.350000 0004 0386 9924Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, USA
| | | | - Juulia Partanen
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
| | - Sanni Ruotsalainen
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
| | - Mitja Kurki
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland ,grid.66859.34Stanley Center for Psychiatric Research, The Broad Institute of Harvard and MIT, Cambridge, MA USA ,grid.32224.350000 0004 0386 9924Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, USA
| | - Lea Martta Urpa
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
| | - Lei Chen
- grid.47100.320000000419368710Department of Genetics, Yale School of Medicine, New Haven, CT USA ,grid.4367.60000 0001 2355 7002McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO USA
| | - Markus Perola
- grid.14758.3f0000 0001 1013 0499Finnish Institute for Health and Welfare, Helsinki, Finland
| | - Veikko Salomaa
- grid.14758.3f0000 0001 1013 0499Finnish Institute for Health and Welfare, Helsinki, Finland
| | - Juha Veijola
- grid.10858.340000 0001 0941 4873Research Unit of Clinical Neuroscience, University of Oulu & Oulu University Hospital, Oulu, Finland
| | - Minna Männikkö
- grid.10858.340000 0001 0941 4873Northern Finland Birth Cohorts, Infrastructure for Population Studies, Faculty of Medicine, University of Oulu, Oulu, Finland
| | - Ira M. Hall
- grid.47100.320000000419368710Department of Genetics, Yale School of Medicine, New Haven, CT USA ,grid.4367.60000 0001 2355 7002McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO USA
| | - Olli Pietiläinen
- grid.66859.34Stanley Center for Psychiatric Research, The Broad Institute of Harvard and MIT, Cambridge, MA USA ,grid.38142.3c000000041936754XStem Cell and Regenerative Biology, Harvard University, Cambridge, USA ,grid.7737.40000 0004 0410 2071Neuroscience Center, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
| | - Jaakko Kaprio
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland ,grid.7737.40000 0004 0410 2071Department of Public Health, University of Helsinki, Helsinki, Finland
| | - Samuli Ripatti
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland ,grid.66859.34Stanley Center for Psychiatric Research, The Broad Institute of Harvard and MIT, Cambridge, MA USA ,grid.32224.350000 0004 0386 9924Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, USA ,grid.7737.40000 0004 0410 2071Department of Public Health, University of Helsinki, Helsinki, Finland
| | - Mark Daly
- grid.7737.40000 0004 0410 2071Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland ,grid.66859.34Stanley Center for Psychiatric Research, The Broad Institute of Harvard and MIT, Cambridge, MA USA ,grid.32224.350000 0004 0386 9924Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, USA
| | - Aarno Palotie
- Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland. .,Stanley Center for Psychiatric Research, The Broad Institute of Harvard and MIT, Cambridge, MA, USA. .,Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
| |
Collapse
|
2
|
Godoy VCSMD, Bellucco FT, Colovati M, Oliveira-Junior HRD, Moysés-Oliveira M, Melaragno MI. Copy number variation (CNV) identification, interpretation, and database from Brazilian patients. Genet Mol Biol 2020; 43:e20190218. [PMID: 33306777 PMCID: PMC7783508 DOI: 10.1590/1678-4685-gmb-2019-0218] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 09/25/2020] [Indexed: 11/22/2022] Open
Abstract
Copy number variations (CNVs) constitute an important class of variation in the
human genome and the interpretation of their pathogenicity considering different
frequencies across populations is still a challenge for geneticists. Since the
CNV databases are predominantly composed of European and non-admixed
individuals, and Brazilian genetic constitution is admixed and ethnically
diverse, diagnostic screenings on Brazilian variants are greatly difficulted by
the lack of populational references. We analyzed a clinical sample of 268
Brazilian individuals, including patients with neurodevelopment disorders and/or
congenital malformations. The pathogenicity of CNVs was classified according to
their gene content and overlap with known benign and pathogenic variants. A
total of 1,504 autosomal CNVs (1,207 gains and 297 losses) were classified as
benign (92.9%), likely benign (1.6%), VUS (2.6%), likely pathogenic (0.2%) and
pathogenic (2.7%). Some of the CNVs were recurrent and with frequency increased
in our sample, when compared to populational open resources of structural
variants: 14q32.33, 22q11.22, 1q21.1, and 1p36.32 gains. Thus, these highly
recurrent CNVs classified as likely benign or VUS were considered non-pathogenic
in our Brazilian sample. This study shows the relevance of introducing CNV data
from diverse cohorts to improve on the interpretation of clinical impact of
genomic variations.
Collapse
Affiliation(s)
| | - Fernanda Teixeira Bellucco
- Universidade Federal de São Paulo, Departamento de Morfologia e Genética, Disciplina de Genética, São Paulo, SP, Brazil
| | - Mileny Colovati
- Universidade Federal de São Paulo, Departamento de Morfologia e Genética, Disciplina de Genética, São Paulo, SP, Brazil
| | | | - Mariana Moysés-Oliveira
- Universidade Federal de São Paulo, Departamento de Morfologia e Genética, Disciplina de Genética, São Paulo, SP, Brazil
| | - Maria Isabel Melaragno
- Universidade Federal de São Paulo, Departamento de Morfologia e Genética, Disciplina de Genética, São Paulo, SP, Brazil
| |
Collapse
|
3
|
Jamaluddin J, Mohd Khair NK, Vinodamaney SD, Othman Z, Abubakar S. Copy number variation of CCL3L1 among three major ethnic groups in Malaysia. BMC Genet 2020; 21:1. [PMID: 31900126 PMCID: PMC6942282 DOI: 10.1186/s12863-019-0803-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2018] [Accepted: 12/17/2019] [Indexed: 11/30/2022] Open
Abstract
Background C-C motif Chemokine Ligand 3 Like 1 (CCL3L1) is a multiallelic copy number variable, which plays a crucial role in immunoregulatory and hosts defense through the production of macrophage inflammatory protein (MIP)-1α. Variable range of the CCL3L1 copies from 0 to 14 copies have been documented in several different populations. However, there is still lack of report on the range of CCL3L1 copy number exclusively among Malaysians who are a multi-ethnic population. Thus, this study aims to extensively examine the distribution of CCL3L1 copy number in the three major populations from Malaysia namely Malay, Chinese and Indian. A diploid copy number of CCL3L1 for 393 Malaysians (Malay = 178, Indian = 90, and Chinese = 125) was quantified using Paralogue Ratio Tests (PRTs) and then validated with microsatellites analysis. Results To our knowledge, this is the first report on the CCL3L1 copy number that has been attempted among Malaysians and the Chinese ethnic group exhibits a diverse pattern of CCL3L1 distribution copy number from the Malay and Indian (p < 0.0001). The CCL3L1 ranged from 0 to 8 copies for both the Malay and Indian ethnic groups while 0 to 10 copies for the Chinese ethnic. Consequently, the CCL3L1 copy number among major ethnic groups in the Malaysian population is found to be significantly varied when compared to the European population (p < 0.0001). The mean/median reported for the Malay, Chinese, Indian, and European are 2.759/2.869, 3.453/3.290, 2.437/1.970 and 2.001/1.940 respectively. Conclusion This study reveals the existence of genetic variation of CCL3L1 in the Malaysian population, and suggests by examining genetic diversity on the ethnicity, and specific geographical region could help in reconstructing human evolutionary history and for the prediction of disease risk related to the CCL3L1 copy number.
Collapse
Affiliation(s)
- Jalilah Jamaluddin
- Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, UPM, 43400, Serdang, Selangor, Malaysia
| | - Nur Khairina Mohd Khair
- Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, UPM, 43400, Serdang, Selangor, Malaysia
| | - Shameni Devi Vinodamaney
- Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, UPM, 43400, Serdang, Selangor, Malaysia
| | - Zulkefley Othman
- Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, UPM, 43400, Serdang, Selangor, Malaysia
| | - Suhaili Abubakar
- Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, UPM, 43400, Serdang, Selangor, Malaysia.
| |
Collapse
|
4
|
Pös O, Budis J, Kubiritova Z, Kucharik M, Duris F, Radvanszky J, Szemes T. Identification of Structural Variation from NGS-Based Non-Invasive Prenatal Testing. Int J Mol Sci 2019; 20:E4403. [PMID: 31500242 PMCID: PMC6769840 DOI: 10.3390/ijms20184403] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 09/03/2019] [Accepted: 09/04/2019] [Indexed: 01/18/2023] Open
Abstract
Copy number variants (CNVs) are an important type of human genome variation, which play a significant role in evolution contribute to population diversity and human genetic diseases. In recent years, next generation sequencing has become a valuable tool for clinical diagnostics and to provide sensitive and accurate approaches for detecting CNVs. In our previous work, we described a non-invasive prenatal test (NIPT) based on low-coverage massively parallel whole-genome sequencing of total plasma DNA for detection of CNV aberrations ≥600 kbp. We reanalyzed NIPT genomic data from 5018 patients to evaluate CNV aberrations in the Slovak population. Our analysis of autosomal chromosomes identified 225 maternal CNVs (47 deletions; 178 duplications) ranging from 600 to 7820 kbp. According to the ClinVar database, 137 CNVs (60.89%) were fully overlapping with previously annotated variants, 66 CNVs (29.33%) were in partial overlap, and 22 CNVs (9.78%) did not overlap with any previously described variant. Identified variants were further classified with the AnnotSV method. In summary, we identified 129 likely benign variants, 13 variants of uncertain significance, and 83 likely pathogenic variants. In this study, we use NIPT as a valuable source of population specific data. Our results suggest the utility of genomic data from commercial CNV analysis test as background for a population study.
Collapse
Affiliation(s)
- Ondrej Pös
- Faculty of Natural Sciences, Comenius University, 841 04 Bratislava, Slovakia.
- Geneton Ltd., 841 04 Bratislava, Slovakia.
| | - Jaroslav Budis
- Geneton Ltd., 841 04 Bratislava, Slovakia.
- Comenius University Science Park, 841 04 Bratislava, Slovakia.
- Slovak Center of Scientific and Technical Information, 811 04 Bratislava, Slovakia.
| | - Zuzana Kubiritova
- Faculty of Natural Sciences, Comenius University, 841 04 Bratislava, Slovakia.
- Institute for Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
| | | | - Frantisek Duris
- Geneton Ltd., 841 04 Bratislava, Slovakia.
- Slovak Center of Scientific and Technical Information, 811 04 Bratislava, Slovakia.
| | - Jan Radvanszky
- Faculty of Natural Sciences, Comenius University, 841 04 Bratislava, Slovakia.
- Institute for Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
| | - Tomas Szemes
- Faculty of Natural Sciences, Comenius University, 841 04 Bratislava, Slovakia.
- Geneton Ltd., 841 04 Bratislava, Slovakia.
- Comenius University Science Park, 841 04 Bratislava, Slovakia.
| |
Collapse
|
5
|
Blair LM, Pickler RH, Anderson C. Integrative Review of Genetic Factors Influencing Neurodevelopmental Outcomes in Preterm Infants. Biol Res Nurs 2015; 18:127-37. [PMID: 26374169 DOI: 10.1177/1099800415605379] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Preterm infants are at elevated risk for a host of neurodevelopmental problems, including disorders that appear later in life. Gene-environment interactions and prematurity may combine to increase the risk for poor neurodevelopmental outcomes. Increasing evidence supports a genetic link to risk for atypical development; however, no genomic risk profiles are currently used for infants without apparent genetic disorders. The purpose of this review was to synthesize recent evidence of genetic associations with atypical neurodevelopmental outcomes that may affect preterm infants who do not have a rare genetic disease. Electronic and hand-search strategies were used to find relevant articles that were English-language, peer-reviewed primary research or meta-analysis reports published between July 2009 and July 2014, involving human participants. Articles included in the analysis (N = 29) used a wide range of study designs and methodologies, complicating the analysis. An integrative-review design was used to synthesize the data. Numerous genes (n = 43) and additional large deletion copy number variants were associated with neurodevelopmental outcomes, including cognition, attention, perception, psychiatric disease, autism spectrum disorder, cerebral palsy, infant behavior, and alterations in brain architecture. The creation of genetic risk profiles for complex disorders of neurodevelopment is presently hindered by inconsistent genetic-association evidence, methodological considerations, reporting problems, and lack of replication. However, several avenues of investigation offer promise, including large (>100 kb) copy number variants and the candidate genes MET, NRG3, and SLC6A4, each of which were reported to have associations with neurodevelopmental outcomes in multiple, high-quality studies.
Collapse
|
6
|
Männik K, Mägi R, Macé A, Cole B, Guyatt A, Shihab HA, Maillard AM, Alavere H, Kolk A, Reigo A, Mihailov E, Leitsalu L, Ferreira AM, Nõukas M, Teumer A, Salvi E, Cusi D, McGue M, Iacono WG, Gaunt TR, Beckmann JS, Jacquemont S, Kutalik Z, Pankratz N, Timpson N, Metspalu A, Reymond A. Copy number variations and cognitive phenotypes in unselected populations. JAMA 2015; 313:2044-54. [PMID: 26010633 PMCID: PMC4684269 DOI: 10.1001/jama.2015.4845] [Citation(s) in RCA: 123] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
IMPORTANCE The association of copy number variations (CNVs), differing numbers of copies of genetic sequence at locations in the genome, with phenotypes such as intellectual disability has been almost exclusively evaluated using clinically ascertained cohorts. The contribution of these genetic variants to cognitive phenotypes in the general population remains unclear. OBJECTIVE To investigate the clinical features conferred by CNVs associated with known syndromes in adult carriers without clinical preselection and to assess the genome-wide consequences of rare CNVs (frequency ≤0.05%; size ≥250 kilobase pairs [kb]) on carriers' educational attainment and intellectual disability prevalence in the general population. DESIGN, SETTING, AND PARTICIPANTS The population biobank of Estonia contains 52,000 participants enrolled from 2002 through 2010. General practitioners examined participants and filled out a questionnaire of health- and lifestyle-related questions, as well as reported diagnoses. Copy number variant analysis was conducted on a random sample of 7877 individuals and genotype-phenotype associations with education and disease traits were evaluated. Our results were replicated on a high-functioning group of 993 Estonians and 3 geographically distinct populations in the United Kingdom, the United States, and Italy. MAIN OUTCOMES AND MEASURES Phenotypes of genomic disorders in the general population, prevalence of autosomal CNVs, and association of these variants with educational attainment (from less than primary school through scientific degree) and prevalence of intellectual disability. RESULTS Of the 7877 in the Estonian cohort, we identified 56 carriers of CNVs associated with known syndromes. Their phenotypes, including cognitive and psychiatric problems, epilepsy, neuropathies, obesity, and congenital malformations are similar to those described for carriers of identical rearrangements ascertained in clinical cohorts. A genome-wide evaluation of rare autosomal CNVs (frequency, ≤0.05%; ≥250 kb) identified 831 carriers (10.5%) of the screened general population. Eleven of 216 (5.1%) carriers of a deletion of at least 250 kb (odds ratio [OR], 3.16; 95% CI, 1.51-5.98; P = 1.5e-03) and 6 of 102 (5.9%) carriers of a duplication of at least 1 Mb (OR, 3.67; 95% CI, 1.29-8.54; P = .008) had an intellectual disability compared with 114 of 6819 (1.7%) in the Estonian cohort. The mean education attainment was 3.81 (P = 1.06e-04) among 248 (≥250 kb) deletion carriers and 3.69 (P = 5.024e-05) among 115 duplication carriers (≥1 Mb). Of the deletion carriers, 33.5% did not graduate from high school (OR, 1.48; 95% CI, 1.12-1.95; P = .005) and 39.1% of duplication carriers did not graduate high school (OR, 1.89; 95% CI, 1.27-2.8; P = 1.6e-03). Evidence for an association between rare CNVs and lower educational attainment was supported by analyses of cohorts of adults from Italy and the United States and adolescents from the United Kingdom. CONCLUSIONS AND RELEVANCE Known pathogenic CNVs in unselected, but assumed to be healthy, adult populations may be associated with unrecognized clinical sequelae. Additionally, individually rare but collectively common intermediate-size CNVs may be negatively associated with educational attainment. Replication of these findings in additional population groups is warranted given the potential implications of this observation for genomics research, clinical care, and public health.
Collapse
Affiliation(s)
- Katrin Männik
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
- Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - Reedik Mägi
- Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - Aurélien Macé
- Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Ben Cole
- University of Minnesota Medical School, Department of Laboratory Medicine & Pathology, 420 Delaware St. SE, Minneapolis, MN 55455, USA
| | - Anna Guyatt
- Bristol Genetic Epidemiology Laboratories, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Hashem A. Shihab
- Bristol Genetic Epidemiology Laboratories, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
- MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Anne M. Maillard
- Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
| | - Helene Alavere
- Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - Anneli Kolk
- Estonian Genome Center, University of Tartu, Tartu, Estonia
- Department of Neurology and Neurorehabilitation, Children's Clinic, Tartu University Hospital, Tartu, Estonia
| | - Anu Reigo
- Estonian Genome Center, University of Tartu, Tartu, Estonia
| | - Evelin Mihailov
- Estonian Genome Center, University of Tartu, Tartu, Estonia
- Department of Neurology and Neurorehabilitation, Children's Clinic, Tartu University Hospital, Tartu, Estonia
| | - Liis Leitsalu
- Estonian Genome Center, University of Tartu, Tartu, Estonia
- Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
| | - Anne-Maud Ferreira
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics, Lausanne, Switzerland
| | - Margit Nõukas
- Estonian Genome Center, University of Tartu, Tartu, Estonia
- Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
| | - Alexander Teumer
- Institute for Community Medicine, University Medicine Greifswald, 17475 Greifswald, Germany
| | - Erika Salvi
- Deparment of Health Sciences, University of Milan, Italy
| | - Daniele Cusi
- Deparment of Health Sciences, University of Milan, Italy
- Institute of Biomedical Technologies, Italian National Research Council, Milan, Italy
| | - Matt McGue
- University of Minnesota Department of Psychology, 75 E. River Rd, Minneapolis, MN 55455, USA
| | - William G. Iacono
- University of Minnesota Department of Psychology, 75 E. River Rd, Minneapolis, MN 55455, USA
| | - Tom R. Gaunt
- Bristol Genetic Epidemiology Laboratories, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
- MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | | | | | - Zoltán Kutalik
- Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics, Lausanne, Switzerland
- Institute of Social and Preventive Medicine, Lausanne University Hospital (CHUV), Switzerland
| | - Nathan Pankratz
- University of Minnesota Medical School, Department of Laboratory Medicine & Pathology, 420 Delaware St. SE, Minneapolis, MN 55455, USA
| | - Nicholas Timpson
- Bristol Genetic Epidemiology Laboratories, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
- MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Andres Metspalu
- Estonian Genome Center, University of Tartu, Tartu, Estonia
- Department of Neurology and Neurorehabilitation, Children's Clinic, Tartu University Hospital, Tartu, Estonia
| | - Alexandre Reymond
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
7
|
Twenty Years of Schizophrenia Research in the Northern Finland Birth Cohort 1966: A Systematic Review. SCHIZOPHRENIA RESEARCH AND TREATMENT 2015; 2015:524875. [PMID: 26090224 PMCID: PMC4452001 DOI: 10.1155/2015/524875] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/11/2015] [Revised: 04/24/2015] [Accepted: 04/29/2015] [Indexed: 11/17/2022]
Abstract
Birth cohort designs are useful in studying adult disease trajectories and outcomes, such as schizophrenia. We review the schizophrenia research performed in the Northern Finland Birth Cohort 1966 (NFBC 1966), which includes 10,934 individuals living in Finland at 16 years of age who have been monitored since each mother's mid-pregnancy. By the age of 44, 150 (1.4%) had developed schizophrenia. There are 77 original papers on schizophrenia published from the NFBC 1966. The early studies have found various risk factors for schizophrenia, especially related to pregnancy and perinatal phase. Psychiatric and somatic outcomes were heterogeneous, but relatively poor. Mortality in schizophrenia is high, especially due to suicides. Several early predictors of outcomes have also been found. Individuals with schizophrenia have alterations in brain morphometry and neurocognition, and our latest studies have found that the use of high lifetime doses of antipsychotics associated with these changes. The schizophrenia research in the NFBC 1966 has been especially active for 20 years, the prospective study design and long follow-up enabling several clinically and epidemiologically important findings. When compared to other birth cohorts, the research in the NFBC 1966 has offered also unique findings on course and outcome of schizophrenia.
Collapse
|
8
|
Costain G, Lionel AC, Fu F, Stavropoulos DJ, Gazzellone MJ, Marshall CR, Scherer SW, Bassett AS. Adult neuropsychiatric expression and familial segregation of 2q13 duplications. Am J Med Genet B Neuropsychiatr Genet 2014; 165B:337-44. [PMID: 24807792 PMCID: PMC4464821 DOI: 10.1002/ajmg.b.32236] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2014] [Accepted: 04/14/2014] [Indexed: 02/05/2023]
Abstract
New genomic disorders associated with large, rare, recurrent copy number variations (CNVs) are being discovered at a rapid pace. Detailed phenotyping and family studies are rare, however, as are data on adult phenotypic expression. Duplications at 2q13 were recently identified as risk factors for developmental delay/autism and reported in the prenatal setting, yet few individuals (all children) have been extensively phenotyped. During a genome-wide CNV study of schizophrenia, we identified two unrelated probands with 2q13 duplications. In this study, detailed phenotyping and genotyping using high-resolution microarrays was performed for 12 individuals across their two families. 2q13 duplications were present in six adults, and co-segregated with clinically significant later-onset neuropsychiatric disorders. Convergent lines of evidence implicated GABAminergic dysfunction. Analysis of the genic content revealed promising candidates for neuropsychiatric disease, including BCL2L11, ANAPC1, and MERTK. Intrafamilial genetic heterogeneity and "second hits" in one family may have been the consequence of assortative mating. Clinical genetic testing for the 2q13 duplication and the associated genetic counseling was well received. In summary, large rare 2q13 duplications appear to be associated with variable adult neuropsychiatric and other expression. The findings represent progress toward clinical translation of research results in schizophrenia. There are implications for other emerging genomic disorders where there is interest in lifelong expression.
Collapse
Affiliation(s)
- Gregory Costain
- Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
| | - Anath C. Lionel
- The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Molecular Genetics and McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada
| | - Fiona Fu
- Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
| | - Dimitri J. Stavropoulos
- Department of Pediatric Laboratory Medicine, Cytogenetics Laboratory, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
| | - Matthew J. Gazzellone
- The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Molecular Genetics and McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada
| | - Christian R. Marshall
- The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Molecular Genetics and McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada
| | - Stephen W. Scherer
- The Centre for Applied Genomics and Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Molecular Genetics and McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada
| | - Anne S. Bassett
- Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
- Department of Psychiatry, University Health Network, Toronto, Ontario, Canada
- Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada
- Correspondence to: Anne S. Bassett, MD, FRCPC, Centre for Addiction and Mental Health, 33 Russell Street, Room 1100, Toronto, Ontario, Canada M5S 2S1.
| |
Collapse
|
9
|
Polimanti R, Piacentini S, Iorio A, De Angelis F, Kozlov A, Novelletto A, Fuciarelli M. Haplotype differences for copy number variants in the 22q11.23 region among human populations: a pigmentation-based model for selective pressure. Eur J Hum Genet 2014; 23:116-23. [PMID: 24667780 DOI: 10.1038/ejhg.2014.47] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2013] [Revised: 02/13/2014] [Accepted: 02/19/2014] [Indexed: 12/17/2022] Open
Abstract
Two gene clusters are tightly linked in a narrow region of chromosome 22q11.23: the macrophage migration inhibitory factor (MIF) gene family and the glutathione S-transferase theta class. Within 120 kb in this region, two 30-kb deletions reach high frequencies in human populations. This gives rise to four haplotypic arrangements, which modulate the number of genes in both families. The variable patterns of linkage disequilibrium (LD) between these copy number variants (CNVs) in diverse human populations remain poorly understood. We analyzed 2469 individuals belonging to 27 human populations with different ethnic origins. Then we correlated the genetic variability of 22q11.23 CNVs with environmental variables. We confirmed an increasing strength of LD from Africa to Asia and to Europe. Further, we highlighted strongly significant correlations between the frequency of one of the haplotypes and pigmentation-related variables: skin color (R(2)=0.675, P<0.001), distance from the equator (R(2)=0.454, P<0.001), UVA radiation (R(2)=0.439, P<0.001), and UVB radiation (R(2)=0.313, P=0.002). The fact that all MIF-related genes are retained on this haplotype and the evidences gleaned from experimental systems seem to agree with the role of MIF-related genes in melanogenesis. As such, we propose a model that explains the geographic and ethnic distribution of 22q11.23 CNVs among human populations, assuming that MIF-related gene dosage could be associated with adaptation to low UV radiation.
Collapse
Affiliation(s)
- Renato Polimanti
- Department of Biology, University of Rome 'Tor Vergata', Rome, Italy
| | - Sara Piacentini
- Department of Biology, University of Rome 'Tor Vergata', Rome, Italy
| | - Andrea Iorio
- Clinical Pathophysiology Center, AFaR - 'San Giovanni Calibita' Fatebenefratelli Hospital, Rome, Italy
| | - Flavio De Angelis
- Department of Biology, University of Rome 'Tor Vergata', Rome, Italy
| | - Andrey Kozlov
- Institute and Museum of Anthropology, M. Lomonosov State University, Moscow, Russia
| | - Andrea Novelletto
- Department of Biology, University of Rome 'Tor Vergata', Rome, Italy
| | - Maria Fuciarelli
- Department of Biology, University of Rome 'Tor Vergata', Rome, Italy
| |
Collapse
|
10
|
Stoll G, Pietiläinen OPH, Linder B, Suvisaari J, Brosi C, Hennah W, Leppä V, Torniainen M, Ripatti S, Ala-Mello S, Plöttner O, Rehnström K, Tuulio-Henriksson A, Varilo T, Tallila J, Kristiansson K, Isohanni M, Kaprio J, Eriksson JG, Raitakari OT, Lehtimäki T, Jarvelin MR, Salomaa V, Hurles M, Stefansson H, Peltonen L, Sullivan PF, Paunio T, Lönnqvist J, Daly MJ, Fischer U, Freimer NB, Palotie A. Deletion of TOP3β, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. Nat Neurosci 2013; 16:1228-1237. [PMID: 23912948 DOI: 10.1038/nn.3484] [Citation(s) in RCA: 134] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2013] [Accepted: 07/01/2013] [Indexed: 02/08/2023]
Abstract
Implicating particular genes in the generation of complex brain and behavior phenotypes requires multiple lines of evidence. The rarity of most high-impact genetic variants typically precludes the possibility of accruing statistical evidence that they are associated with a given trait. We found that the enrichment of a rare chromosome 22q11.22 deletion in a recently expanded Northern Finnish sub-isolate enabled the detection of association between TOP3B and both schizophrenia and cognitive impairment. Biochemical analysis of TOP3β revealed that this topoisomerase was a component of cytosolic messenger ribonucleoproteins (mRNPs) and was catalytically active on RNA. The recruitment of TOP3β to mRNPs was independent of RNA cis-elements and was coupled to the co-recruitment of FMRP, the disease gene product in fragile X mental retardation syndrome. Our results indicate a previously unknown role for TOP3β in mRNA metabolism and suggest that it is involved in neurodevelopmental disorders.
Collapse
Affiliation(s)
- Georg Stoll
- Department of Biochemistry, University of Würzburg, Germany
| | - Olli P H Pietiläinen
- Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.,Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.,National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland
| | - Bastian Linder
- Department of Biochemistry, University of Würzburg, Germany
| | - Jaana Suvisaari
- National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland
| | - Cornelia Brosi
- Department of Biochemistry, University of Würzburg, Germany
| | - William Hennah
- Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.,National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland
| | - Virpi Leppä
- Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Minna Torniainen
- National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland
| | - Samuli Ripatti
- Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.,Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Sirpa Ala-Mello
- Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland
| | - Oliver Plöttner
- Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
| | | | - Annamari Tuulio-Henriksson
- National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland
| | - Teppo Varilo
- Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.,National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland
| | - Jonna Tallila
- Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK
| | | | - Matti Isohanni
- Department of Psychiatry, Institute of Clinical Medicine, University of Oulu, Finland
| | - Jaakko Kaprio
- Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.,National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland.,Department of Public Health, University of Helsinki, Helsinki, Finland
| | - Johan G Eriksson
- National Institute for Health and Welfare, Chronic Disease Epidemiology and Prevention, Helsinki, Finland.,Department of General Practice and Primary Health Care, University of Helsinki, Finland.,Vasa Central Hospital, Finland.,Folkhälsan Research Centre, Helsinki, Finland.,Unit of General Practice, Helsinki University Central Hospital, Finland
| | - Olli T Raitakari
- Department of Clinical Physiology and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, Finland.,Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku and Turku University Central Hospital, Turku, Finland
| | - Terho Lehtimäki
- Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, Finland
| | - Marjo-Riitta Jarvelin
- Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom.,MRC-HPA Centre for Environment and Health, Imperial College London, London, United Kingdom.,National Institute of Health and Welfare, Oulu, Finland.,Institute of Health Sciences, University of Oulu, Oulu, Finland
| | - Veikko Salomaa
- National Institute for Health and Welfare, Department of Chronic Disease Prevention, Helsinki/Turku, Finland
| | | | | | - Leena Peltonen
- Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.,Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.,National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland.,University of Helsinki, Department of Medical Genetics, Helsinki, Finland
| | - Patrick F Sullivan
- Departments of Genetics, Psychiatry and Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Tiina Paunio
- Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.,National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland.,University of Helsinki and Helsinki University Central Hospital, Department of Psychiatry, Helsinki, Finland
| | - Jouko Lönnqvist
- National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland.,Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland
| | - Mark J Daly
- Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Utz Fischer
- Department of Biochemistry, University of Würzburg, Germany
| | - Nelson B Freimer
- Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, California, USA
| | - Aarno Palotie
- Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.,Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.,Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| |
Collapse
|
11
|
Cousminer DL, Berry DJ, Timpson NJ, Ang W, Thiering E, Byrne EM, Taal HR, Huikari V, Bradfield JP, Kerkhof M, Groen-Blokhuis MM, Kreiner-Møller E, Marinelli M, Holst C, Leinonen JT, Perry JR, Surakka I, Pietiläinen O, Kettunen J, Anttila V, Kaakinen M, Sovio U, Pouta A, Das S, Lagou V, Power C, Prokopenko I, Evans DM, Kemp JP, St Pourcain B, Ring S, Palotie A, Kajantie E, Osmond C, Lehtimäki T, Viikari JS, Kähönen M, Warrington NM, Lye SJ, Palmer LJ, Tiesler CM, Flexeder C, Montgomery GW, Medland SE, Hofman A, Hakonarson H, Guxens M, Bartels M, Salomaa V, Murabito JM, Kaprio J, Sørensen TI, Ballester F, Bisgaard H, Boomsma DI, Koppelman GH, Grant SF, Jaddoe VW, Martin NG, Heinrich J, Pennell CE, Raitakari OT, Eriksson JG, Smith GD, Hyppönen E, Järvelin MR, McCarthy MI, Ripatti S, Widén E. Genome-wide association and longitudinal analyses reveal genetic loci linking pubertal height growth, pubertal timing and childhood adiposity. Hum Mol Genet 2013; 22:2735-47. [PMID: 23449627 PMCID: PMC3674797 DOI: 10.1093/hmg/ddt104] [Citation(s) in RCA: 145] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2012] [Accepted: 02/25/2013] [Indexed: 01/18/2023] Open
Abstract
The pubertal height growth spurt is a distinctive feature of childhood growth reflecting both the central onset of puberty and local growth factors. Although little is known about the underlying genetics, growth variability during puberty correlates with adult risks for hormone-dependent cancer and adverse cardiometabolic health. The only gene so far associated with pubertal height growth, LIN28B, pleiotropically influences childhood growth, puberty and cancer progression, pointing to shared underlying mechanisms. To discover genetic loci influencing pubertal height and growth and to place them in context of overall growth and maturation, we performed genome-wide association meta-analyses in 18 737 European samples utilizing longitudinally collected height measurements. We found significant associations (P < 1.67 × 10(-8)) at 10 loci, including LIN28B. Five loci associated with pubertal timing, all impacting multiple aspects of growth. In particular, a novel variant correlated with expression of MAPK3, and associated both with increased prepubertal growth and earlier menarche. Another variant near ADCY3-POMC associated with increased body mass index, reduced pubertal growth and earlier puberty. Whereas epidemiological correlations suggest that early puberty marks a pathway from rapid prepubertal growth to reduced final height and adult obesity, our study shows that individual loci associating with pubertal growth have variable longitudinal growth patterns that may differ from epidemiological observations. Overall, this study uncovers part of the complex genetic architecture linking pubertal height growth, the timing of puberty and childhood obesity and provides new information to pinpoint processes linking these traits.
Collapse
Affiliation(s)
| | - Diane J. Berry
- Centre for Paediatric Epidemiology and Biostatistics, MRC Centre for Epidemiology of Child Health, UCL Institute of Child Health, London, UK
| | - Nicholas J. Timpson
- The Medical Research Council (MRC) Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine
| | - Wei Ang
- School of Women's and Infants' Health, The University of Western Australia, Perth, WA, Australia
| | - Elisabeth Thiering
- Institute of Epidemiology I, Helmholtz Zentrum München— German Research Center for Environmental Health, Neuherberg, Germany
| | - Enda M. Byrne
- Queensland Institute of Medical Research, Brisbane, Australia
| | - H. Rob Taal
- The Generation R Study Group
- Department of Epidemiology
- Department of Pediatrics, Erasmus Medical Center, Rotterdam, The Netherlands
| | | | | | | | - Maria M. Groen-Blokhuis
- Netherlands Twin Register, Department of Biological Psychology, VU University, Amsterdam, The Netherlands
| | - Eskil Kreiner-Møller
- Copenhagen Prospective Studies on Asthma in Childhood, Health Sciences, University of Copenhagen, Copenhagen University Hospital, Gentofte, Denmark
| | - Marcella Marinelli
- Center for Research in Environmental Epidemiology (CREAL), Barcelona, Catalonia, Spain
- Hospital del Mar Research Institute (IMIM), Barcelona, Catalonia, Spain
- CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Catalonia, Spain
| | - Claus Holst
- Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark
| | | | - John R.B. Perry
- Genetics of Complex Traits, Exeter medical school, University of Exeter, Exeter, UK
- Wellcome Trust Centre for Human Genetics
- Department of Twin Research and Genetic Epidemiology, King's College London, London, UK
| | - Ida Surakka
- Institute for Molecular Medicine, Finland (FIMM)
- Department of Chronic Disease Prevention
| | - Olli Pietiläinen
- Institute for Molecular Medicine, Finland (FIMM)
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
| | - Johannes Kettunen
- Institute for Molecular Medicine, Finland (FIMM)
- Department of Chronic Disease Prevention
| | - Verneri Anttila
- Institute for Molecular Medicine, Finland (FIMM)
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA
- Analytical and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Marika Kaakinen
- Institute of Health Sciences
- Biocenter Oulu, University of Oulu, Oulu, PO Box 5000, FI-90014, Finland
| | - Ulla Sovio
- Department of Epidemiology and Biostatistics, School of Public Health
- Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
| | - Anneli Pouta
- Biocenter Oulu, University of Oulu, Oulu, PO Box 5000, FI-90014, Finland
| | - Shikta Das
- Department of Epidemiology and Biostatistics, School of Public Health
| | - Vasiliki Lagou
- Wellcome Trust Centre for Human Genetics
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Chris Power
- Centre for Paediatric Epidemiology and Biostatistics, MRC Centre for Epidemiology of Child Health, UCL Institute of Child Health, London, UK
| | - Inga Prokopenko
- Wellcome Trust Centre for Human Genetics
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - David M. Evans
- The Medical Research Council (MRC) Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine
| | - John P. Kemp
- The Medical Research Council (MRC) Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Beate St Pourcain
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Susan Ring
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Aarno Palotie
- Institute for Molecular Medicine, Finland (FIMM)
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA
| | - Eero Kajantie
- Department of Chronic Disease Prevention
- Hospital for Children and Adolescents, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
| | - Clive Osmond
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
| | - Terho Lehtimäki
- Department of Clinical Chemistry, Fimlab Laboratories, University Hospital and University of Tampere, Finland
| | | | - Mika Kähönen
- Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku; Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Finland
| | - Nicole M. Warrington
- School of Women's and Infants' Health, The University of Western Australia, Perth, WA, Australia
| | - Stephen J. Lye
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Lyle J. Palmer
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Carla M.T. Tiesler
- Institute of Epidemiology I, Helmholtz Zentrum München— German Research Center for Environmental Health, Neuherberg, Germany
- Division of Metabolic Diseases and Nutritional Medicine, Ludwig-Maximilians-University of Munich, Dr von Hauner Children's Hospital, Munich, Germany
| | - Claudia Flexeder
- Institute of Epidemiology I, Helmholtz Zentrum München— German Research Center for Environmental Health, Neuherberg, Germany
| | | | | | - Albert Hofman
- The Generation R Study Group
- Department of Epidemiology
| | - Hakon Hakonarson
- Center for Applied Genomics
- Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Mònica Guxens
- Center for Research in Environmental Epidemiology (CREAL), Barcelona, Catalonia, Spain
- Hospital del Mar Research Institute (IMIM), Barcelona, Catalonia, Spain
- CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Catalonia, Spain
| | - Meike Bartels
- Netherlands Twin Register, Department of Biological Psychology, VU University, Amsterdam, The Netherlands
| | | | | | - Joanne M. Murabito
- Department of Medicine, Section of General Internal Medicine, Boston University School of Medicine, Boston, MA, USA
| | - Jaakko Kaprio
- Institute for Molecular Medicine, Finland (FIMM)
- Department of Public Health
- Department of Mental Health & Substance Abuse Services, National Institute for Health and Welfare, Helsinki, Finland
| | - Thorkild I.A. Sørensen
- Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark
- The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
| | - Ferran Ballester
- CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Catalonia, Spain
- Division of Environment and Health, Center for Public Health Research (CSISP), Valencia, Spain
- School of Nursing, University of Valencia, Valencia, Spain
| | - Hans Bisgaard
- Copenhagen Prospective Studies on Asthma in Childhood, Health Sciences, University of Copenhagen, Copenhagen University Hospital, Gentofte, Denmark
| | - Dorret I. Boomsma
- Netherlands Twin Register, Department of Biological Psychology, VU University, Amsterdam, The Netherlands
| | - Gerard H. Koppelman
- Department of Pediatric Pulmonology and Pediatric Allergology, GRIAC Research Institute, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Struan F.A. Grant
- Center for Applied Genomics
- Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Vincent W.V. Jaddoe
- The Generation R Study Group
- Department of Epidemiology
- Department of Pediatrics, Erasmus Medical Center, Rotterdam, The Netherlands
| | | | - Joachim Heinrich
- Institute of Epidemiology I, Helmholtz Zentrum München— German Research Center for Environmental Health, Neuherberg, Germany
| | - Craig E. Pennell
- School of Women's and Infants' Health, The University of Western Australia, Perth, WA, Australia
| | - Olli T. Raitakari
- Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku; Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Finland
| | - Johan G. Eriksson
- Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland
- Department of Chronic Disease Prevention
- Unit of General Practice
- Folkhalsan Research Centre, Helsinki, Finland
| | - George Davey Smith
- The Medical Research Council (MRC) Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine
| | - Elina Hyppönen
- Centre for Paediatric Epidemiology and Biostatistics, MRC Centre for Epidemiology of Child Health, UCL Institute of Child Health, London, UK
| | - Marjo-Riitta Järvelin
- Institute of Health Sciences
- Biocenter Oulu, University of Oulu, Oulu, PO Box 5000, FI-90014, Finland
- Department of Epidemiology and Biostatistics, MRC Health Protection Agency (HPA) Centre for Environment and Health, School of Public Health, Imperial College, London, UK
- Unit of Primary Care, Oulu University Hospital, Kajaanintie 50, PO Box 20, FI-90220 Oulu, 90029 OYS, Finland
- Department of Children and Young People and Families, National Institute for Health and Welfare, Aapistie 1, Box 310, FI-90101 Oulu, Finland
| | - Mark I. McCarthy
- Wellcome Trust Centre for Human Genetics
- Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LJ, UK
| | - Samuli Ripatti
- Institute for Molecular Medicine, Finland (FIMM)
- Department of Chronic Disease Prevention
- The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
| | | | | |
Collapse
|
12
|
|
13
|
Hochstenbach R, Buizer-Voskamp JE, Vorstman JAS, Ophoff RA. Genome arrays for the detection of copy number variations in idiopathic mental retardation, idiopathic generalized epilepsy and neuropsychiatric disorders: lessons for diagnostic workflow and research. Cytogenet Genome Res 2011; 135:174-202. [PMID: 22056632 DOI: 10.1159/000332928] [Citation(s) in RCA: 92] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/08/2022] Open
Abstract
We review the contributions and limitations of genome-wide array-based identification of copy number variants (CNVs) in the clinical diagnostic evaluation of patients with mental retardation (MR) and other brain-related disorders. In unselected MR referrals a causative genomic gain or loss is detected in 14-18% of cases. Usually, such CNVs arise de novo, are not found in healthy subjects, and have a major impact on the phenotype by altering the dosage of multiple genes. This high diagnostic yield justifies array-based segmental aneuploidy screening as the initial genetic test in these patients. This also pertains to patients with autism (expected yield about 5-10% in nonsyndromic and 10-20% in syndromic patients) and schizophrenia (at least 5% yield). CNV studies in idiopathic generalized epilepsy, attention-deficit hyperactivity disorder, major depressive disorder and Tourette syndrome indicate that patients have, on average, a larger CNV burden as compared to controls. Collectively, the CNV studies suggest that a wide spectrum of disease-susceptibility variants exists, most of which are rare (<0.1%) and of variable and usually small effect. Notwithstanding, a rare CNV can have a major impact on the phenotype. Exome sequencing in MR and autism patients revealed de novo mutations in protein coding genes in 60 and 20% of cases, respectively. Therefore, it is likely that arrays will be supplanted by next-generation sequencing methods as the initial and perhaps ultimate diagnostic tool in patients with brain-related disorders, revealing both CNVs and mutations in a single test.
Collapse
Affiliation(s)
- R Hochstenbach
- Division of Biomedical Genetics, Department of Medical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands.
| | | | | | | |
Collapse
|